Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 109

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 109
---
922 Ordinary Shares issued and outstanding
as of April 1, 2025.

| 60 |

| (1) | Assumes that all Ordinary Shares being registered under the registration                                                                
 statement of which this prospectus forms a part are sold in this offering, and that none of the selling stockholders acquire additional 
 Ordinary Shares after the date of this prospectus and prior to completion of this offering. The information set forth in the footnotes  
 is based upon our information and belief, the records of the Company and the selling stockholder’s filing with the SEC, if any.         |

| (2) | The selling shareholder holds (i) warrants issued by us in prior                                                                              
 transactions which entitle the selling shareholder to purchase an aggregate of 518,720,000 Ordinary Shares (in the form of Depositary         
 Shares), and (ii) Replacement Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 324,740,000 Ordinary    
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 9.99%, which does not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts      
 and percentages in the table do not give effect to the 9.99% beneficial ownership limitation, if applicable. The principal business address   
 of Bigger Capital Fund, LP is 11700 West Charleston Blvd, #170-659, Las Vegas, NV 89135.                                                      |

| (3) | The selling shareholder holds (i) warrants issued by us in a prior transaction which entitle the selling                                       
 shareholder to purchase an aggregate of 3,200,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Replacement                     
 Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 169,900,000 Ordinary Shares (in the form of Depositary 
 Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation of 4.99%, which does                
 not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder and its affiliates    
 owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts and percentages          
 in the table do not give effect to the 4.99%